{"id":898722,"date":"2025-10-22T08:23:02","date_gmt":"2025-10-22T12:23:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/genedx-showcases-leadership-in-genomic-newborn-screening-at-icons-2025\/"},"modified":"2025-10-22T08:23:02","modified_gmt":"2025-10-22T12:23:02","slug":"genedx-showcases-leadership-in-genomic-newborn-screening-at-icons-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/genedx-showcases-leadership-in-genomic-newborn-screening-at-icons-2025\/","title":{"rendered":"GeneDx Showcases Leadership in Genomic Newborn Screening at ICoNS 2025"},"content":{"rendered":"

<\/p>\n

GeneDx Showcases Leadership in Genomic Newborn Screening at ICoNS 2025<\/b><\/p>\n

\nData from more than 22,000 newborns reinforce GeneDx\u2019s role spearheading the adoption of genomic newborn screening (gNBS) from research to clinical practice<\/p>\n

GAITHERSBURG, Md.–(BUSINESS WIRE<\/a>)–
\nGeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced data and presentations at theInternational Consortium on Newborn Sequencing (ICoNS), underscoring the company\u2019s leadership in driving genomic newborn screening (gNBS) from research into real-world clinical implementation.<\/p>\n

\nAs the laboratory partner behind the leading gNBS programs \u2013 including the Genomic Uniform-screening Against Rare Diseases In All Newborns (GUARDIAN)<\/a> Study, Early Check<\/a>\u2019s pilot phase, the NIH\u2019s Building Evidence and Collaboration for GenOmics in Nationwide Newborn Screening (BEACONS)<\/a> Network, and Florida\u2019s Sunshine Genetics Program \u2013 GeneDx is powering the future of genomic sequencing from research to real-word clinical adoption. Collectively, these programs represent the largest and most comprehensive gNBS efforts in the U.S., with approximately 22,000 newborns screened to date.<\/p>\n

\nEarlier this year GeneDx acquired Fabric Genomics enabling flexible solutions \u2013 from comprehensive end to end testing to interpretation-as-a-service \u2013 supporting partners and health systems globally and accelerating GeneDx\u2019s international expansion and driving further adoption of gNBS.<\/p>\n

\n\u201cGeneDx is proud to be the trusted partner behind major gNBS programs in the U.S.,\u201d said Katherine Stueland, President and Chief Executive Officer of GeneDx. \u201cOur leadership in this space \u2013 from supporting pioneering research to enabling clinical adoption in Florida \u2013 reflects our mission to make genomic insights available to every family at birth and drive true longevity from the earliest moment possible. Genomic newborn screening represents the next frontier in preventive medicine, and GeneDx is uniquely equipped to deliver it at scale.\u201d<\/p>\n

\nAt ICoNS, Britt Johnson, PhD, FACMG, Senior Vice President of Medical Affairs at GeneDx, will present during the Fast Track session: Laboratory Insights from GUARDIAN: Scalable, Equitable Approach to Genomic Newborn Screening in over 17,000 Newborns Reveals Actionable Insights.<\/i><\/b> The presentation will highlight real-world learnings from GeneDx\u2019s laboratory implementation of gNBS for the GUARDIAN study, including the operational, technical, and equity frameworks that are informing national and state-level programs. Powered by GeneDx Infinity\u2122 and advanced clinical analysis automation, the GUARDIAN study demonstrates that gNBS can be performed with short turnaround times, equitable access, and high diagnostic yield.<\/p>\n

\n\u201cThrough GUARDIAN, GeneDx\u2019s experience confirms that large-scale genomic newborn screening is feasible, scalable, and ready for real-world adoption to drive meaningful clinical impact,\u201d said Dr. Johnson. \u201cOur findings show that early use of genomic newborn screening identifies conditions that traditional newborn screening doesn\u2019t include \u2013 offering families answers before symptoms, leading to accelerate treatment pathways and significant cost savings for our healthcare system.\u201d<\/p>\n

\n\u201cEnrolling more than 20,000 newborns in the GUARDIAN study marks a pivotal milestone in demonstrating the feasibility and impact of genomic newborn screening,\u201d said Wendy Chung, MD, PhD, Principal Investigator of the GUARDIAN Study and Chief of the Department of Pediatrics at Boston Children\u2019s Hospital. \u201cWe\u2019ve shown that genomic screening can identify serious conditions early, often before symptoms appear, allowing families to begin life-saving interventions. Just as importantly, we\u2019ve learned invaluable lessons that continue to refine and strengthen this approach, bringing us one step closer to making genomic newborn screening part of standard care for every baby.\u201d<\/p>\n

\nBuilt on GeneDx Infinity\u2122, the largest and most diverse rare-disease dataset \u2013 comprising nearly one million sequenced exomes and genomes and more than seven million phenotypic datapoints \u2013 GeneDx\u2019s platform delivers the clinical accuracy, speed, and scalability required to make gNBS a standard of care.<\/p>\n

GeneDx collaborated on the following projects that will be presented at ICoNS:<\/b><\/p>\n